Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Net Cash Flow (2016 - 2025)

Wave Life Sciences' Net Cash Flow history spans 11 years, with the latest figure at $405.9 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 4737.5% year-over-year to $405.9 million; the TTM value through Dec 2025 reached $300.0 million, up 194.35%, while the annual FY2025 figure was $300.0 million, 194.35% up from the prior year.
  • Net Cash Flow reached $405.9 million in Q4 2025 per WVE's latest filing, up from -$12.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $405.9 million in Q4 2025 to a low of -$88.8 million in Q1 2022.
  • Average Net Cash Flow over 5 years is $20.9 million, with a median of -$15.8 million recorded in 2024.
  • The largest YoY upside for Net Cash Flow was 4737.5% in 2025 against a maximum downside of 205.34% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $26.7 million in 2021, then plummeted by 131.95% to -$8.5 million in 2022, then surged by 806.46% to $60.4 million in 2023, then crashed by 114.5% to -$8.8 million in 2024, then soared by 4737.5% to $405.9 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Net Cash Flow are $405.9 million (Q4 2025), -$12.2 million (Q3 2025), and -$34.6 million (Q2 2025).